Meyers Michael L. 4
4 · Syndax Pharmaceuticals Inc · Filed Feb 14, 2020
Insider Transaction Report
Form 4
Meyers Michael L.
SVP, Chief Development Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-02-12+50,825→ 50,825 totalExercise: $9.47Exp: 2030-02-12→ Common Stock (50,825 underlying)
Footnotes (1)
- [F1]1/48th of the shares subject to the option shall vest monthly over a four-year period.